 |
|
|
Dear [Dr. Firstname A. Lastname,XX]:
Thank you for attending [Conference Name] on [XX/XX/XXXX]
and your commitment to exploring the depths of gout.
As you know, long-term control of hyperuricemia to a serum
uric acid level of <6 mg/dL is a key to managing gout.(1)
We encourage you to further explore how ULORIC powerfully
lowers serum uric acid to target levels of <6 mg/dL (2)
today.
ULORIC was studied in controlled trials of 6 months and 1
year and in open-label extension trials for up to 5 years.
(2) 45% of patients receiving ULORIC 40 mg and between 67%
and 74% of patients receiving ULORIC 80 mg achieved a serum
uric acid level of<6 mg/dL in 3 clinical trials.(2)
Individual Results May Vary based on factors such as
baseline serum uric acid levels.
Visit ULORIC.com now to learn more.
Indication
ULORIC is a xanthine oxidase (XO) inhibitor indicated for
the chronic management of hyperuricemia in patients with
gout.
ULORIC is not recommended for the treatment of asymptomatic
hyperuricemia.
Important Safety Information
| • |
ULORIC is contraindicated in patients being treated with
azathioprine, mercaptopurine, or theophylline.
|
| • |
An increase in gout flares is frequently observed during
initiation of anti-hyperuricemic agents, including ULORIC.
If a gout flare occurs during treatment, ULORIC need not be
discontinued. Prophylactic therapy (i.e.–NSAIDs or
colchicine) upon initiation of treatment may bebeneficial
for up to six months.
|
| • |
Cardiovascular Events: In randomized controlled studies,
there was a higher rate of cardiovascular thromboembolic
events (cardiovascular deaths, non-fatal myocardial
infarctions, and non-fatal strokes) in patients treated with
ULORIC [0.74 per 100 P-Y (95% CI 0.36-1.37)] than allopurinol
[0.60 per 100 P-Y (95% CI 0.16-1.53)]. A causal relationship
with ULORIC has not been established. Monitor for signs and
symptoms of MI and stroke.
|
| • |
Liver Enzyme Elevations: In randomized controlled studies,
transaminase elevations greater than 3 times the upper limit
of normal (ULN) were observed (AST: 2%, 2%, and ALT: 3%, 2%
in ULORIC and allopurinol-treated patients, respectively).
No dose-effect relationship for these transaminase elevations
was noted. Laboratory assessment of liver function is
recommended at, for example, 2 and 4 months following initiation
of ULORIC and periodically thereafter.
|
| • |
Adverse reactions occurring in at least 1% of ULORIC-treated
patients, and, at least 0.5% greater than placebo, are liver
function abnormalities, nausea, arthralgia, and rash. |
Please see full Prescribing Information for ULORIC.
References:
| 1. |
Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat
compared with allopurinol inpatients with hyperuricemia and gout.
N Engl J Med. 2005;353:2450-2461.
|
| 2. |
ULORIC®(febuxostat) full prescribing information, February
2009.
|
If you are a Vermont prescriber, please click here for the Vermont
long form regarding AWP.
You received this e-mail because you registered to receive e-mail
updates from Takeda Pharmaceuticals North America, Inc.
Click here to unsubscribe from receiving future e-mail messages
from Takeda about ULORIC, the diseases and conditions it treats,
and related treatment options, or write to us at Program
Headquarters, P.O. Box 3670, Highland Park, MI 48203 to be
removed from our mailing list.
|
|
ULORIC® is a registered trademark of Teijin Pharma Limited and used under license by Takeda Pharmaceuticals America, Inc.
©2010 Takeda Pharmaceuticals North America, Inc. This site is intended for use by U.S. residents only.
Takeda Pharmaceuticals North America, Inc. One Takeda Parkway Deerfield, IL 60015 (224) 554-6500
Please do not reply to this message. E-mails sent to this account will not be read.
Takeda Pharmaceuticals North America, Inc. respects your
personal health information. The information you provide may
be used to send you health-related materials and to develop
products, services, and programs. Takeda, or third parties
working on our behalf, will not sell or rent personal health
information. Our Privacy Statement can be read and printed by
clicking here.
TXF-00673 |
|
|
|
